MAT Troubleshooting
Prepare for the January 2026 animal-testing suppression mandate with CellMade’s authoritative MAT framework. We resolve matrix interference and provide Ph. Eur. 2.6.30/USP validation to ensure a seamless transition to human-relevant safety standards.
As the biopharmaceutical industry approaches the mandatory January 2026 deadline for suppressing animal-based pyrogen tests, CellMade Laboratories provides an authoritative framework for transitioning to human-relevant safety standards. Our services are engineered to resolve the technical complexities of the Monocyte Activation Test (MAT)—including matrix interference, (1-3)-ß-D-glucan (BDG) management, and cytotoxicity—through a structured 3-phase roadmap. By integrating targeted Non-Endotoxin Pyrogen (NEP) profiling and mechanistic PBMC assessments, we deliver the empirical evidence required for Ph. Eur. 2.6.30 verification and FDA/USP validation. This consultative approach provides a "Reproducibility Premium" for complex parenteral therapies, ensuring your safety strategy is scientifically justified, GMP-compliant, and fully aligned with global 3Rs principles.
